Answers are grounded in this paper and cite their sources.
Sirolimus (Rapamune; Wyeth-Ayerst Laboratories, Madison, NJ), introduced clinically in 1999, is an immunosuppressive macrolide antibiotic. It appears to block T-cell activation and proliferation by binding the mammalian target of rapamycin protein, inhibiting the interleukin-2–mediated signal transduction pathway. Adverse effects include hyperlipidemia (hypercholesterolemia and hypertriglyceridemia), elevated liver transaminases, and bone marrow suppression (thrombocytopenia, leukopenia, and anemia). Sirolimus is metabolized by the cytochrome P-450 3A4 (CYP3A4) system (1). Atorvastatin (Lipitor; Pfizer, Inc., New York, NY), a structural analog of 3-hydroxy-3-methylglutaryl (HMG) coenzyme A (CoA) inhibitor, selectively and competitively inhibits HMG-CoA reductase, thereby inhibiting synthesis of mevalonic acid, a precursor of cholesterol. Atorvastatin is frequently prescribed for hypercholesterolemia, including corticosteroid- and calcineurin inhibitor-associated hypercholesterolemia. Approximately 80% to 90% of atorvastatin is metabolized by the CYP3A4 system (2). The most common adverse effects associated with atorvastatin use are headache, rash, and gastrointestinal disturbances. More significant, but less common and probably dose related, are hepatotoxicity and myopathy. Although both drugs are metabolized by the CYP3A4 substrate, there currently are no published reports describing the interaction between the two drugs. Therefore, in the current report we present the co-administration of sirolimus and atorvastatin to a pancreatic islet transplant (PIT) recipient with hypercholesterolemia, resulting in elevated serum sirolimus trough concentrations requiring reduction of sirolimus dosing. A 36-year-old woman with type 1 diabetes mellitus, who despite maximal exogenous insulin therapy suffered from metabolic instability and hypoglycemic unawareness, underwent PIT. Posttransplant immunosuppression consisted of a triple-drug regimen including induction therapy with daclizumab (Zenapax; Hoffman La Roche, Nutley, NJ), 1 mg/kg before transplantation followed by additional intravenous injections every 14 days for a total of five doses, and maintenance immunosuppression using tacrolimus (Prograf; Fujisawa Healthcare, Inc., Deerfield, IL) and sirolimus (Rapamune). Tacrolimus was administered twice daily to maintain a 12-hr trough level of 3 to 5 ng/mL. Sirolimus was given orally once daily to attain 24-hr trough levels of 12 to 15 ng/mL for the first 3 months and then 7 to 10 ng/mL indefinitely. For the first 5 postoperative months, the sirolimus dose was between 8 and 11 mg/day, with resultant serum sirolimus trough levels between 6.1 and 20.5 ng/mL. Concomitantly administered medications included acyclovir, Axid (Eli Lilly, Indianapolis, IN), lithium, Ritalin (Ciba-Geigy Corp., Summit, NJ), Elavil (Merck, Sharpe & Dohme, Reddington, NJ), Effexor (Wyeth-Ayerst), Zofran (Glaxo Wellcome, Inc., Research Triangle Park, NC), Prinivil (Merck & Co., Inc., Whitehouse, NJ), Valcyte (Hoffman La Roche), nystatin, Trental (Hoechst Marion Roussel, Kansas City, MO), Nexium (AstraZenica, Essex, CT), and Feosol (Smith Kline Beecham, Pittsburgh, PA). Routine lipid evaluation 6 months after PIT and the initiation of sirolimus administration demonstrated hypercholesterolemia with a cholesterol level of 241 mg/dL, a triglyceride level of 91 mg/dL, and a ratio of low-density lipoprotein to high-density lipoprotein of 2.05. Antihypercholesterolemia therapy was initiated with atorvastatin. Six weeks after the initiation of atorvastatin therapy, it was noted that the patient’s sirolimus trough concentration had increased to 20.5 ng/mL (Fig. 1). Therefore, the sirolimus dose was reduced and trough levels were regularly followed (Fig. 1). After 3 months of atorvastatin therapy, the sirolimus dose had been halved, with sirolimus trough concentrations being maintained at a therapeutic level (range, 8.3–34.3 ng/mL) (Fig. 1). Figure 1: Relationship between sirolimus dose (solid black area), atorvastatin dose (dashed line), and sirolimus blood level (dots) in a pancreatic islet transplant recipient.The mean sirolimus trough concentration before the initiation of atorvastatin treatment was 13.3 ng/mL; after initiation of atorvastatin, it was 17.7 ng/mL (P =0.003 with one-tailed Student t test). The mean daily dose of sirolimus before atorvastatin therapy was 10.4 mg (1.5 mg/kg/day). The mean daily dose after atorvastatin therapy was 6.7 mg (0.9 mg/kg/day); by the end of 5 months, the patient’s dose had been decreased to 5 mg/day, with the highest recorded sirolimus trough concentration being 34.3 ng/mL. No adverse effects were associated with elevated sirolimus trough levels in this patient. It is well known that both atorvastatin and sirolimus are metabolized by the CYP3A4 enzymes, and one would surmise that the co-administration of these drugs would lead to elevated levels of sirolimus and atorvastatin. The degree of interaction between these two, however, had not been described previously. Here, we have found that co-administration of these two drugs initially led to a doubling of the serum sirolimus trough concentration, requiring alteration in sirolimus dosing. No adverse effects from atorvastatin or sirolimus were clinically evident. There is a theoretical increase in risk of developing myopathy and subsequent rhabdomyolysis with the co-administration of atorvastatin and sirolimus. More confidently predicting the degree of interaction between these two drugs will require studying additional patients who took both atorvastatin and sirolimus concurrently. The true risk of myopathy and rhabdomyolysis would also be borne out by further study. Neal R. Barshes Sarah E. Goodpastor John A. Goss
No takes yet. Share an insight, caveat, or question.
Barshes et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: